Effect of combined Sorafenib and transarterial chemoembolization on advanced primary hepatocellular carcinoma

Objective To observe the effect and side effects of combined Sorafenib and transarterial chemoembolization（TACE） on advanced primary hepatocellular carcinoma（HCC）. Methods Therapeutic effects of combined oral Sorafenib and TACE for over 1 month on advanced primary HCC in 65 patients admitted to our hospital were retrospectively analyzed according to the RECIST criteria and the side effects were recorded. Results The overall survival rate of the patients was 66.2%.Among the 43 survived patients,HCC was stable in 31 and partially remitted in 7,with a disease control rate of 88.4% and an adverse reaction rate of 78.5%.The disease was significantly relieved after expectant treatment. Conclusion Combined Sorafenib and TACE therapy is safe and effective for advanced primary HCC.